6 results

Take-up of biosimilars in the Irish health system has been held back by the lack of Government encouragement and inertia among medical practitioners. Photograph: Benis Arapovic/Getty

Efforts to pull together a national policy on biosimilars remain stymied somewhere in the Department of Health but at least some moves are finally bei(...)

Simon Harris: The Minister for Health has said his department is developing a national biosimilar policy. Photograph: Dara Mac Donaill

When the rheumatoid arthritis drug Benepali came on the Irish market last year, it was the first to test a new drug pricing agreement between the Gove(...)

Medicine costs: a significant  portion of the €750 million in savings expected under a drug pricing deal between now and mid-2020 may not be delivered. Photograph: Getty

The Government risks losing out on hundreds of millions of euro in savings on its drug bill because of the failure to buy generic alternatives to exp(...)

 Industry sources say the State  lost between €4 million and €5 million by the delay in reducing the price of Pfizer’s  blockbuster arthritis drug  Enbrel. Photograph: Paul Faith/AFP/Getty Images

The introduction of a biosimilar drug into the Irish market will save the Health Service Executive (HSE) millions of euro this year alone. In Septem(...)

Pfizer’s  Enbrel lost patent protection in Europe earlier this year. Biogen introduced Benepali into the Irish market in September

The price of one of the world’s most popular drugs is falling 30 per cent in Ireland under the terms of a recently signed pricing agreement. Enbrel,(...)

Pfizer plans to build a five-storey biopharma manufacturing unit in two phases, adding more than 34,500sq m to its current footprint on what is already one of the largest biotechnology plants in the world. Photograph:   Andrew Kelly/Reuters

Pfizer will create up to 350 new jobs with its latest multimillion euro expansion of its Grange Castle Campus in Dublin. The US company is looking to(...)